Non-Invasive Cardiac Evaluation in Heart Failure Patients Using Magnetic Resonance Imaging: A Feasibility Study

Shors, Stephanie M.; Cotts, William; Pavlovic-Surjancev, Biljana; Gheorghiade, Mihai; Carr, James C.; McCarthy, Richard M.; Pereles, Scott; Finn, Paul

doi:10.1007/s10741-005-7540-6

Cited by 5 publications

(4 citation statements)

References 30 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 in Ref [6]). Unfortunately, we could not evaluate cardiac MRI-T2* value after successful iron chelation owing to transfer to another hospital, but her LVEF, determined by the echocardiogram which has been suggested to strongly correlate with MRI-determined EF [15], became normal. Our results need to be confirmed by studies in large numbers of patients with iron overload, and the correlation among parameters, including serum ferritin, and normalization of cardiac function and/or liver images should be addressed.…”

mentioning

confidence: 93%

Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload

2009

View full text Add to dashboard Cite

mentioning

confidence: 93%

Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload

2009

View full text Add to dashboard Cite

“…In the failing heart, the presence of viable, but dysfunctional, myocardium is relatively common and is an important predictor of improvement of systolic function (reverse remodeling) in response to medical and revascularization therapies (171)(172)(173)(174). Certain causes of dysfunctional myocardium are known, such as stunning hibernation due to chronic ischemia (175).…”

Section: Outlook and Challengesmentioning

confidence: 99%

“…Perturbed energetics due to micronutrient deficiencies may also be responsible for dysfunctional myocardium. The chronic improvement or normalization of contractility of dysfunctional myocardium may be used as a surrogate end point to assess the effects of micronutrients in HF (171,173,174,176).…”

Section: Outlook and Challengesmentioning

confidence: 99%

Micronutrient Deficiencies

Soukoulis

Dihu

Sole

et al. 2009

Journal of the American College of Cardiology

Self Cite

122

View full text Add to dashboard Cite

Heart failure (HF) is a common, disabling, and costly disease. Despite major advances in medical therapy, morbidity and mortality remain high, in part because current pharmacological regimens may not fully address some unique requirements of the heart for energy. The heart requires a continuous supply of energy-providing substrates and amino acids in order to maintain its function. In HF, defects in substrate metabolism and cardiac energy and substrate utilization may contribute to contractile dysfunction. HF is often accompanied by a deficiency in key micronutrients required for unimpeded energy transfer. Correcting these deficits has been proposed as a method to limit or even reverse the progressive myocyte dysfunction and/or necrosis in HF. This review summarizes the existing HF literature with respect to supplementation trials of key micronutrients involved in cardiac metabolism: coenzyme Q10, l-carnitine, thiamine, and amino acids, including taurine. Studies using a broader approach to supplementation are also considered. Although some of the results are promising, none are conclusive. There is a need for a prospective trial to examine the effects of micronutrient supplementation on morbidity and mortality in patients with HF.

show abstract

“…Cardiac viability imaging with magnetic resonance imaging provides an accurate, highresolution method for detecting myocardial necrosis. This may be particularly valuable in evaluating inotropes or vasodilators and monitoring for their potential detrimental effects in AHFS (29).…”

Section: Assessment Of Coronary Perfusionmentioning

confidence: 99%

Acute Heart Failure Syndromes and Coronary Perfusion

Beohar

Erdogan

Lee

et al. 2008

Journal of the American College of Cardiology

Self Cite

View full text Add to dashboard Cite

Acute heart failure syndromes (AHFS), with a high post-discharge mortality and rehospitalization rate, represent a significant public health burden. The treatment of patients hospitalized with AHFS often includes the use of vasoactive medications such as inotropes and vasodilators. Although such agents are frequently used, their safety and efficacy remain controversial. A significant number of patients with heart failure have underlying coronary artery disease and may be at greater risk from hemodynamic alterations that can diminish coronary perfusion. In AHFS, the relationship among vasoactive medications, coronary perfusion, and potential myocardial injury needs further investigation. Newer techniques now available to evaluate coronary perfusion should provide guidance for the evaluation of existing and future vasoactive therapies for AHFS.

show abstract

Non-Invasive Cardiac Evaluation in Heart Failure Patients Using Magnetic Resonance Imaging: A Feasibility Study

Cited by 5 publications

References 30 publications

Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload

Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload

Micronutrient Deficiencies

Acute Heart Failure Syndromes and Coronary Perfusion

Contact Info

Product

Resources

About